Table 4.
Solid dosage forms of biopharmaceuticals in SAS drug delivery systems.
| Year | Active Compound | Co-Solvent | Solid Dosage Form | Observations | Ref. |
|---|---|---|---|---|---|
| 1993 | Insulin | DMSO DMFA 1 |
N/A | 90% of the particles with a diameter smaller than 4 µm 10% of the particles with a diameter smaller than 1 µm Blood glucose level decreases over the time |
[120] |
| 1999 | Lysozyme | DCM 2 | (a) P(LLA) 3 (b) PLGA |
PCA (a) 250 µm < Diameter < 500 µm (b) 5 µm < Diameter < 60 µm CO2 at high velocity through an annular region in a coaxial nozzle results in spherical and uniform particles |
[124] |
| 2001 | Insulin | (a) DCM (b) DCM- DMSO (50:50,%v/v) |
P(LLA) 3 | (a) 1 µm < Diameter < 3 µm (b) 0.5 µm < Diameter < 2 µm |
[118] |
| 2009 | Lysozyme | Water/EtOH | N/A | SEDS Fiber formation at higher pressures 0.1 µm < PSD < 0.4 µm Lysozyme activity was recovered from all spherical particles |
[126] |
| 2009 | BSA | DCM | P(LLA) 3 | PS < 2.5 µm The secondary BSA structure is not affected BSA content of 17.11% |
[127] |
| 2009 | Lysozyme | DMSO | N/A | PCA: PS < 100 nm GAS: 233 nm < PS < 302 nm Formation of the lysozyme particles involves spinodal decomposition |
[128] |
| 2012 | Insulin | DMSO/Acetone | HPMCP 4 | 138 nm < PS < 342 nm EE up to 100% 10. 76% < Insulin loading < 16.04% |
[129] |
1 N-N-Dimethylformamide; 2 Dichloromethane; 3 Poly-(L-lactide); 4 Hydroxypropyl methyl cellulose phthalate.